Sutro Biopharma, Inc. - Expanded Access Programs

Expanded Access Intelligence

Official Statements

Score contribution: 100 — 1 supporting sources.

Score 1001 references

Featured Reference

Compassionate Use Access | Sutro Biopharma, Inc.Opens in new window

“At Sutro Biopharma, investigational drugs may be provided under the following conditions: patients who are diagnosed with a serious or life-threatening disease, who have exhausted approved treatment options, and who are not eligible for clinical trials. Sutro Biopharma will consider providing individual patients compassionate use access to an investigational medicine outside of a clinical trial only when all of the criteria below are met.”

EAP Related Articles from Sponsor

Score contribution: 80 — 7 supporting sources.

Score 807 references

Featured Reference

Sutro Biopharma Announces New Positive Data from the ...Opens in new window

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),today announced that its research collaborators presented data on anti-leukemic activity from the compassionate use of luveltamab tazevibulin (luvelta), a novel folate receptor-α (FR-α) targeting ADC, in pediatric patients with relapsed/refractory CBFA2T3-GLIS2 (CBF/GLIS) acute myeloid leukemia (AML), commonly known as RAM phenotype AML.

Sutro Biopharma Announces Presentation of STRO-002 Data from ...Source

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that its research collaborators at Fred Hutchinson Cancer Research Center presented data from the Compassionate Use Program on anti-leukemic activity of STRO-002, a novel folate receptor-α (FR-α) targeting ADC, in pediatric patients with relapsed/refractory CBFA2T3-GLIS2 (CBF/GLIS) acute myeloid leukemia (AML), commonly known as RAM phenotype AML, in an oral presentation at the 64th American Society of Hematology Annual Meeting and Exposition (ASH 2022) in New Orleans, LA. STRO-002 was provided to 17 pediatric patients with CBF/GLIS subtype AML on a compassionate use basis.

REFRaME-P1-Patients | Sutro Biopharma, Inc.Source

Sutro continues to provide luveltamab tazevibulin through Compassionate Use Access

Sitemap | Sutro Biopharma, Inc.Source

- Patients - [Patient Resources](https://www.sutrobio.com/patient-resources/) - [Commitment To Patients](https://www.sutrobio.com/commitment-to-patients/) - [Compassionate Use Access](https://www.sutrobio.com/compassionate-use-access/)

Sutro Biopharma Announces Initiation of the Registration-enabling ...Source

With my focus on the biology of AML, I am honored to have been a part of making this medicine available to patients in dire need via a compassionate use mechanism sponsored by Sutro, through which we have seen encouraging results in this devastating disease.

Sutro Biopharma Reports Third Quarter 2023 Financial Results ...Source

Patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) AML, a highly refractory and uniformly fatal subtype of acute myeloid leukemia found exclusively in infants and young children, were treated with luvelta under compassionate use. Preliminary results from compassionate use of luvelta in this ultra rare indication suggested that luvelta was well tolerated as a monotherapy agent and in combination with standard cancer therapies.

Partner with Right2Hope

Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.

Talk to Our Team Explore Programs